PTC Therapeutics
PTCT
99 hedge funds and large institutions have $1.07B invested in PTC Therapeutics in 2014 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 23 increasing their positions, 26 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
83% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 18
78% more capital invested
Capital invested by funds: $601M → $1.07B (+$471M)
18% more funds holding
Funds holding: 84 → 99 (+15)
12% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$25.6M |
| 2 |
TAM
Tocqueville Asset Management
New York
|
+$9.37M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$8.56M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$7.46M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$7.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$22.2M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$7.16M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$6.79M |
| 4 |
O
OrbiMed
New York
|
-$4.66M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.96M |
PTCT Hedge Fund Activity: Q3 2014 in Review
99 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2014, worth a combined $1.07B — up 78% from $601M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new PTCT positions and 18 closed out — a net gain of 15 holders — while 23 added to existing stakes and 26 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $25.6M. The largest seller was Credit Suisse, cutting an estimated $22.2M.
- 99 institutional investors held PTC Therapeutics (PTCT) as of Q3 2014, up from 84 in Q2 2014.
- Funds reported $1.07B of PTC Therapeutics stock for Q3 2014, up 78% quarter-over-quarter.
- 33 funds opened new PTC Therapeutics positions in Q3 2014 and 18 closed out, a net change of +15 holders.
- The largest PTC Therapeutics buyer in Q3 2014 was Wellington Management Group, an estimated $25.6M added.
- The largest PTC Therapeutics seller in Q3 2014 was Credit Suisse, an estimated $22.2M sold.
Based on aggregated 13F filings for Q3 2014.